In the latest trading session, 0.41 million Spyre Therapeutics Inc (NASDAQ:SYRE) shares changed hands as the company’s beta touched 2.92. With the company’s most recent per share price at $37.28 changed hands at -$2.07 or -5.27% at last look, the market valuation stands at $1.92B. SYRE’s current price is a discount, trading about -28.67% off its 52-week high of $47.97. The share price had its 52-week low at $8.75, which suggests the last value was 76.53% up since then. When we look at Spyre Therapeutics Inc’s average trading volume, we note the 10-day average is 0.42 million shares, with the 3-month average coming to 478.02K.
Analysts gave the Spyre Therapeutics Inc (SYRE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SYRE as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Spyre Therapeutics Inc’s EPS for the current quarter is expected to be -0.89.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Instantly SYRE was in red as seen in intraday trades today. With action 3.77%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 73.21%, with the 5-day performance at 3.77% in the green. However, in the 30-day time frame, Spyre Therapeutics Inc (NASDAQ:SYRE) is 21.58% up. Looking at the short shares, we see there were 8.41 million shares sold at short interest cover period of 13.78 days.
The consensus price target for the stock as assigned by Wall Street analysts is 40, meaning bulls need an upside of 6.8% from its recent market value. According to analyst projections, SYRE’s forecast low is 40 with 50 as the target high. To hit the forecast high, the stock’s price needs a -34.12% plunge from its current level, while the stock would need to soar -7.3% for it to hit the projected low.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
Data shows that the Spyre Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -5.13% over the past 6 months, a 84.26% in annual growth rate that is considerably higher than the industry average of 17.10%. Year-over-year growth is forecast to reach 295.00% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 3.5M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.60%. The 2024 estimates are for Spyre Therapeutics Inc earnings to increase by 90.51%.
SYRE Dividends
Spyre Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 7.1903% or 3.26 million shares worth $76.6 million as of 2024-06-30.
